Insider Buying: Crescita Therapeutics Inc. (TSE:CTX) Director Acquires 86,000 Shares of Stock

Crescita Therapeutics Inc. (TSE:CTX) Director Jose Darocha bought 86,000 shares of the company’s stock in a transaction that occurred on Friday, December 27th. The stock was bought at an average cost of C$0.60 per share, for a total transaction of C$51,436.60.

Crescita Therapeutics Stock Performance

Shares of CTX stock traded up C$0.04 during mid-day trading on Friday, hitting C$0.60. 79,900 shares of the stock were exchanged, compared to its average volume of 22,886. The stock’s fifty day simple moving average is C$0.58 and its two-hundred day simple moving average is C$0.58. The company has a debt-to-equity ratio of 6.02, a quick ratio of 2.29 and a current ratio of 3.37. Crescita Therapeutics Inc. has a 12-month low of C$0.36 and a 12-month high of C$0.69. The stock has a market capitalization of C$11.63 million, a price-to-earnings ratio of -4.00 and a beta of 1.69.

About Crescita Therapeutics

Crescita Therapeutics Inc, a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp.